| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | buserelin acetate (Suprefact Depot®) |
| Formulation | 9.45 mg implant |
| Reference number | 71 |
| Indication | Treatment of advanced hormone-dependent prostatic carcinoma |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 21/01/2008 |